Gilead's B/F/TAF single-tablet HIV treatment shown effective and well-tolerated in Asian adults, including those with HIV/HBV coinfection.
Gilead Sciences announces new data supporting the use of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) single-tablet regimen for treating HIV in treatment-naïve and experienced adults in Asia, including those with HIV/HBV coinfection. A multiregional study in Taiwan, South Korea, and Singapore shows the regimen is well-tolerated and effective in adults of Asian descent.
June 27, 2024
3 Articles